Summary: Non-NS5A Inhibitor, Sofosbuvir-Containing Regimen-Experienced, Genotype 1 Patients Without Cirrhosis
Recommended and alternative regimens listed by evidence level and alphabetically for:
Non-NS5A Inhibitor, Sofosbuvir-Containing Regimen-Experienced, Genotype 1 Patients Without Cirrhosis
|
|
RECOMMENDED
|
DURATION
|
RATING 
|
|
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)/voxilaprevir (100mg) for genotype 1a patients
|
12 weeks
|
I, A
|
|
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg)a, regardless of subtype
|
12 weeks
|
IIa, B
|
|
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg) for genotype 1b patients
|
12 weeks
|
IIa, B
|
|
ALTERNATIVE
|
DURATION
|
RATING
|
|
Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) plus weight-based ribavirin, except in simeprevir failures
|
12 weeks
|
IIa, B
|
|
a Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information.
|
